Key clinical point: Abrocitinib can be considered a treatment option for patients with moderate-to-severe atopic dermatitis (AD) regardless of prior response to dupilumab.
Major finding: At 12 weeks, ≥75% improvement in the Eczema Area and Severity Index was achieved by 80.0% (95% CI 62.5%-97.5%) and 67.7% (95% CI 51.3%-84.2%) of prior dupilumab nonresponders and 93.5% (95% CI 86.3%-100.0%) and 90.2% (95% CI 84.1%-96.3%) of prior dupilumab responders who received 200 mg and 100 mg abrocitinib, respectively. The most common treatment emergent adverse events were nasopharyngitis, nausea, acne, and headache.
Study details: This phase 3 study, JADE EXTEND , included 203 patients with moderate-to-severe AD who were randomly assigned to receive 200 mg or 100 mg abrocitinib once-daily after receiving dupilumab for 14 weeks in JADE COMPARE .
Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees or shareholders of Pfizer and other authors reported ties with various sources, including Pfizer.
Source: Shi VY et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab ( JADE EXTEND). J Am Acad Dermatol. 2022 (Apr 16). Doi: 10.1016/j.jaad.2022.04.009